| Document |
Document Title |
|
WO/2013/093019A1 |
The present invention relates to a compound of general formula (I) in which: - R1 and R2 are simultaneously or independently H, OH, OCH3 or a C1-C5 alkyl radical, - R3 and R4 are simultaneously CH3, - or R3 is H and R4 is CH3, CH2CH3 or ...
|
|
WO/2013/089460A1 |
The present invention relates to a novel chemical compound having an acridine structure, and to an organic light-emitting diode using same, and more particularly, to a novel chemical compound having an acridine structure, and to an organ...
|
|
WO/2013/044123A1 |
The present invention provides for methods for therapeutic use of dimeric compound B3C and related compounds to treat Parkinson's disease (PD) and Parkinsonism. B3C is neuroprotective and has utility as a therapeutic agent for the treatm...
|
|
WO/2013/033430A1 |
Acridine containing cispiaiin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective eisp!aiin compounds to the nucleus in cancer ceils is discl...
|
|
WO/2013/011954A1 |
An organic electroluminescence element using a compound represented by general formula (1) in a light-emitting layer exhibits a high emission efficiency and is inexpensive to manufacture. (1) At least one of R1 through R8 and R17 represe...
|
|
WO/2012/147330A1 |
[Problem] To provide an organic compound, as a material for a highly efficient and highly durable organic electroluminescent element, which exhibits excellent hole injection and transportation capabilities and has electron stopping abili...
|
|
WO/2012/141249A1 |
An organic electroluminescent element using a compound represented by general formula (AA) has high luminous efficiency and excellent color purity, while being suppressed in chromaticity change due to driving deterioration. (In the formu...
|
|
WO/2012/137741A1 |
A method for purifying an organic material, which can sublimate and purify an organic material having a high sublimation temperature and high heat resistance within a short time with high purity and high yield. The method comprises: redu...
|
|
WO/2012/128898A1 |
Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA s...
|
|
WO/2012/049828A1 |
An aromatic heterocyclic derivative represented by formula (1); a material for an organic electroluminescent element; and an organic electroluminescent element comprising the derivative or the material.
|
|
WO/2012/036573A2 |
The present invention relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmace...
|
|
WO/2012/033061A1 |
Provided is an organic electroluminescent element having superior luminous efficiency and durability as well as a low drive voltage and superior heat resistance. The organic electroluminescent element has a pair of electrodes formed on a...
|
|
WO/2012/031534A1 |
Disclosed are 1,2,3,4,5,6,7,8-octohydro-9-phenylacetamidoacridine and salts thereof, as well as a preparation method and pharmaceutical use thereof. The compound can be used in the preparation of a medicament for treating cardiovascular ...
|
|
WO/2012/032990A1 |
To provide a compound which contributes to providing a photoelectric conversion element that exhibits high photoelectric conversion efficiency, low dark current, and rapid response, and which does not decompose during vapor deposition. T...
|
|
WO/2012/029253A1 |
Nitrogen-containing aromatic heterocyclic derivative represented by the formula. X1 to X3 represent a single bond, CRaRb, NRc, an oxygen atom, or a sulfur atom. In the case where all of X1 to X3 have a single bond, at least one of Ara, A...
|
|
WO/2012/024670A2 |
The disclosure provides methods of treating glioblastoma, methods of screening for compounds that treat glioblastoma, and pharmaceutical compositions useful in the treatment of glioblastoma.
|
|
WO/2011/156889A1 |
There is provided modulators of Nrf2 protein which comprises a compound which binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2. There is also provided pharmaceutical compos...
|
|
WO/2011/155169A1 |
Provided are organic compounds that, as materials for high efficiency, high durability organic electroluminescence elements, have excellent positive hole-injection and/or -transport capabilities, are able to block electrons, are very sta...
|
|
WO/2011/127406A2 |
The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Ha...
|
|
WO/2011/123911A1 |
The present invention can be used as an antitumoral medicament for testosterone-dependent tumours, in particular prostate cancer. The invention is a molecular compound formed by testosterone molecules chemically linked to molecules of a ...
|
|
WO/2011/105700A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same. Since the organic electroluminescent compounds exhibit high luminous efficiency in blue color, and excellent life proper...
|
|
WO/2011/099606A1 |
A photoelectric element includes a conductive layer, an organic photoelectric layer, a blocking layer and a transparent conductive layer, the organic photoelectric layer contains a p type organic photoelectric material having a glass tra...
|
|
WO/2011/093603A1 |
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits good luminous efficiency and excellent life property, it may be used...
|
|
WO/2011/086178A1 |
The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
|
|
WO/2011/070177A2 |
Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFRα receptor molecules, ...
|
|
WO/2011/062182A1 |
Provided are a photo-acid generator having good development properties and a cation polymerization initiator having good curing properties, and also provided are a resist composition and cation polymerizable composition that use the phot...
|
|
WO/2011/060228A1 |
Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to s...
|
|
WO/2011/051950A1 |
N-substituted 9-aminoacridine and bis-acridino derivatives containing electron- withdrawing groups (EWG) or electron-donating groups (EDG), including amino acid residues, and one-pot methods for their synthesis are disclosed. The derivat...
|
|
WO/2011/034071A1 |
Disclosed is a process for producing an oxidation reaction product of an aromatic compound, which has excellent environmental load reduction performance, excellent cost reduction performance and the like. Specifically disclosed is a proc...
|
|
WO/2010/151006A1 |
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same. Since the organic electroluminescent compound disclosed herein exhibits good luminescence efficiency and excellent life pro...
|
|
WO/2010/147319A2 |
The present invention relates to an acridine derivative and to an organic electroluminescent element comprising the same. More specifically, the present invention relates to an acridine derived compound in which an acridine moiety and an...
|
|
WO/2010/145696A1 |
The present invention relates to methods for detecting presence, or absence, of blood. Specifically, the present invention relates to methods for detecting the presence, or absence, of blood, comprising applying a solution comprising lum...
|
|
WO/2010/062107A1 |
Provided is an electroluminescent device including an organic layer interposed between an anode and a cathode on a substrate, wherein the organic layer includes an electroluminescent layer containing one or more dopant compound(s) of for...
|
|
WO/2010/050779A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells comprising the same. The organic electroluminescent compounds according to the present invention exhibit high luminou...
|
|
WO/2010/045270A2 |
The invention provides methods and compositions for detecting and measuring the amount of autophagosomes in cells or tissues, including biopsy samples, in vitro, in situ and/or in vivo. By detecting and measuring the amount of autophagos...
|
|
WO/2009/103798A1 |
The application relates to cationic compounds of formula (Ia) where R1 to R9 and X- are defined as indicated in claim 1. Said compounds, some of which have not yet been described in the prior art, are suitable for coloring keratinous fib...
|
|
WO/2009/097433A1 |
There are described novel rhodamine dye compounds and imaging members and imaging methods, including thermal imaging members and imaging methods, utilizing the compounds. The dye compounds exhibit a first color when in the crystalline fo...
|
|
WO/2009/067417A1 |
A method is provided for N-alkylation of acridine compounds, typically with a 1,3- propane sultone alkylating reagent, in ionic liquid solvents to provide the corresponding acridinium compounds in high yeild.
|
|
WO/2009/041519A1 |
An organic-inorganic composite material capable of attaining a charge-separated state enhanced in life and stability as compared with that of conventional organic-inorganic composite materials, more particularly, an organic-inorganic com...
|
|
WO/2009/030715A1 |
The invention relates tosubstitutedarylsulphonylaminomethylphosphonic acid derivativesof general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparinga...
|
|
WO/2009/026858A1 |
The invention relates to the synthesis and evaluation of novel organic products as anti-parasitic, anti-fungal and anti-viral agents. More specifically, the invention relates to novel derivatives of 10-alyl- (I), 10-(3methyl-2-butenyl)- ...
|
|
WO/2008/124749A1 |
The present invention relates to methods and kits for detecting an analyte in a test sample using acridinium-9-carboxylate aryl esters.
|
|
WO/2008/109840A1 |
This invention is directed to, for example, compounds of formula (I): wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically accep...
|
|
WO/2008/068540A1 |
The present invention relates to new phenylsulfamoyl benzamide derivatives of formula (I), wherein R1-R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which a...
|
|
WO/2008/067055A2 |
Chemiluminescent acridinium esters are provided which are fast light emitting and hydrolytically stable. The chemiluminescent acridinium esters are useful labels in assays for detecting or quantifying analytes.
|
|
WO/2008/064011A1 |
A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and to...
|
|
WO/2008/012782A2 |
The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hy...
|
|
WO/2008/004529A1 |
A novel fluorescent amino acid derivative that can be synthesized through a simple process and that can be excited by visible rays, especially those of blue laser light region, exhibiting high photostability; and a process for producing ...
|
|
WO/2007/136125A1 |
Disclosed are: a composition for inhibiting the transcription of an extracellular matrix gene, comprising a compound having a heterocyclic ring represented by the formula (I) and an inert carrier; and others.
|
|
WO/2007/125952A1 |
Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (I) In the formula, R1 represents an optionally substituted lower alkyl group; Y represents -S(O)n- (w...
|
